HOPE Therapeutics, Inc. is a development-stage healthcare delivery company that aims to develop a network of interventional psychiatry clinics offering ketamine transcranial magnetic stimulation (TMS) and other therapies for patients with suicidal depression and related disorders. The company plans to pair these services with a digital therapeutic-enabled platform designed to enhance the benefits of NMDA-targeted drug therapy. HOPE Therapeutics has partnered with NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for central nervous system disorders such as suicidal bipolar depression, chronic pain, and PTSD. NRx is currently developing NRX-101, an FDA-designated Breakthrough Therapy for treatment-resistant bipolar depression and chronic pain, which also has potential as a non-opioid treatment for chronic pain and for complicated UTI. The company has initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression based on results from well-controlled clinical trials conducted by the US National Institutes of Health and French health authorities. Matthew Duffy, Chief Business Officer at NRx Pharmaceuticals and Co-Chief Executive Officer at HOPE Therapeutics, is leading the companies' efforts to develop these innovative treatments.
https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-announce-dr-jonathan-javitt-and-dr-david-feifel-to-present-keynote-address-beyond-ketamine-monotherapy-combined-interventional-treatment-of-suicidal-depressi-302344042.html